Clinical Trial Update: Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Velcade (bortezomib) and temsirolimus for relapsed or refractory non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Temsirolimus (temsirolimus)
• Velcade (bortezomib)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Non-Hodgkins Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-08-21